H. Res. 1318 is a commemorative House resolution expressing support for designating May 2026 as “Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month.” The resolution describes progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) as rare, adult-onset, rapidly progressing neurodegenerative diseases that affect movement, balance, speech, swallowing, cognition, vision, and mood, and that are often misdiagnosed or diagnosed late. It also notes the burden on patients, families, caregivers, and clinicians, and emphasizes the need for greater public awareness, education, and support.
The resolution states that the House supports research into diagnosis, prevention, treatments, and cures for PSP and CBD, and recognizes the work of families, volunteers, healthcare professionals, researchers, and organizations serving the affected community. It does not create a new program, mandate spending, or change eligibility for benefits; instead, it is an expression of congressional support and recognition tied to an awareness month.
Its practical legal impact on state laws is minimal to none, because it is a federal House resolution and is nonbinding. It does not amend state statutes, regulate healthcare practice, or impose requirements on states, insurers, providers, or federal agencies. Any effect would be indirect, mainly by encouraging awareness campaigns, advocacy, and research attention.
The general sentiment reflected in the bill text is strongly supportive and sympathetic toward patients and caregivers. The resolution frames the diseases as serious, under-recognized, and in need of more research and better care, and it praises the resilience of the affected community. No committee debate or recorded votes were provided, so there is no evidence of opposition in the available materials.
Because there are no transcripts or votes, there are no documented points of contention in the record provided. The only potential area of policy interest is the resolution’s emphasis on research, diagnosis, and specialized neurology care, but the measure itself is purely ceremonial and appears noncontroversial based on the available context.
This resolution has no direct effect on state law and does not amend any statutes. It is a nonbinding congressional expression of support for an awareness month, with indirect impact limited to public awareness, advocacy, and encouragement of research and support services for people affected by PSP and CBD.
The bill appears broadly positive and compassionate in tone, with support from a bipartisan group of House sponsors and no recorded opposition in the provided materials. The resolution emphasizes the seriousness of the diseases, the needs of patients and caregivers, and the importance of research and awareness.
No specific contention is documented in the provided committee or vote history. Because the measure is a ceremonial awareness resolution, it does not appear to raise major policy disputes. The only substantive themes are calls for more research, better diagnosis, and specialized care, which are presented as shared goals rather than points of disagreement.